Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hol ...

On June 30, 2026, AbCellera Biologics Inc. appointed Lynn Seely, M.D., as an independent Class III director to its Board, with her term running until the 2029 annual meeting of shareholders. The Board ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AbCellera Biologics Inc. (ABCL) been one of those stocks this year? A quick ...

ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Investors in AbCellera Biologics Inc (Symbol: ABCL) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

On margins, Kotak expects most NBFCs to report year-on-year net interest margin (NIM) expansion of 9-80 basis points as lower ...

On June 17, 2026, AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement.

Dr. Hansen explained that "the main scientific risk for ABCL-635 is whether or not we can achieve sufficient target engagement," with proof-of-concept data expected to provide clarity in mid-2026.